JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $7
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:EVH) with a Overweight and lowers the price target from $13 to $7.
JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:EVH) with a Overweight and lowers the price target from $13 to $7.